Viridian Therapeutics, Inc. (NASDAQ:VRDN) Stock Position Increased by Rhumbline Advisers

Rhumbline Advisers lifted its position in Viridian Therapeutics, Inc. (NASDAQ:VRDN) by 4.6% during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 104,559 shares of the company’s stock after buying an additional 4,621 shares during the period. Rhumbline Advisers owned approximately 0.13% of Viridian Therapeutics worth $1,409,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently modified their holdings of VRDN. Loomis Sayles & Co. L P bought a new stake in shares of Viridian Therapeutics in the 4th quarter worth $26,845,000. Price T Rowe Associates Inc. MD raised its stake in shares of Viridian Therapeutics by 2,847.7% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,326,811 shares of the company’s stock worth $25,436,000 after buying an additional 1,281,799 shares in the last quarter. Deep Track Capital LP raised its stake in shares of Viridian Therapeutics by 20.6% in the 4th quarter. Deep Track Capital LP now owns 4,522,741 shares of the company’s stock worth $86,701,000 after buying an additional 771,796 shares in the last quarter. FMR LLC raised its stake in shares of Viridian Therapeutics by 6.2% in the 4th quarter. FMR LLC now owns 11,881,912 shares of the company’s stock worth $227,776,000 after buying an additional 698,434 shares in the last quarter. Finally, Parkman Healthcare Partners LLC raised its stake in shares of Viridian Therapeutics by 155.9% in the 4th quarter. Parkman Healthcare Partners LLC now owns 1,087,634 shares of the company’s stock worth $20,850,000 after buying an additional 662,634 shares in the last quarter.

Viridian Therapeutics Stock Performance

Shares of VRDN stock opened at $15.00 on Thursday. Viridian Therapeutics, Inc. has a 1-year low of $9.90 and a 1-year high of $27.20. The company has a current ratio of 19.49, a quick ratio of 19.49 and a debt-to-equity ratio of 0.05. The company has a market capitalization of $1.22 billion, a price-to-earnings ratio of -3.90 and a beta of 0.41. The stock’s fifty day simple moving average is $13.63 and its 200-day simple moving average is $15.96.

Viridian Therapeutics (NASDAQ:VRDN) last issued its quarterly earnings results on Tuesday, May 6th. The company reported ($0.87) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.95) by $0.08. Viridian Therapeutics had a negative return on equity of 70.61% and a negative net margin of 102,092.39%. The business had revenue of $0.07 million for the quarter, compared to the consensus estimate of $0.16 million. The company’s quarterly revenue was up .0% compared to the same quarter last year. On average, sell-side analysts predict that Viridian Therapeutics, Inc. will post -4.03 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on VRDN shares. HC Wainwright reissued a “buy” rating and issued a $34.00 price objective on shares of Viridian Therapeutics in a research note on Wednesday, April 23rd. JMP Securities decreased their target price on Viridian Therapeutics from $42.00 to $38.00 and set a “market outperform” rating on the stock in a report on Wednesday, May 7th. The Goldman Sachs Group decreased their target price on Viridian Therapeutics from $31.00 to $27.00 and set a “buy” rating on the stock in a report on Wednesday, May 7th. Royal Bank Of Canada decreased their target price on Viridian Therapeutics from $46.00 to $45.00 and set an “outperform” rating on the stock in a report on Wednesday, May 7th. Finally, Needham & Company LLC restated a “buy” rating and issued a $36.00 target price on shares of Viridian Therapeutics in a report on Tuesday, May 20th. One analyst has rated the stock with a hold rating and nine have issued a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $37.56.

About Viridian Therapeutics

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.